Moclobemide in social phobia: A controlled dose-response trial

Journal of Clinical Psychopharmacology

Volumn 17, Issue 4, 1997, Pages 247-254

  Noyes Jr , Russell ^a,q   Moroz, Georges ^b   Davidson, Jonathan R T ^c   Liebowitz, Michael R ^d   Davidson, Arnold ^b   Siegel, Judith ^b   Bell, Jon ^e   Cain, John W ^f   Curlik, Sharon M ^g   Kent, Thomas A ^h   Bruce Lydiard, R ⁱ   Mallinger, Alan G ^j   Pollack, Mark H ^k   Rapaport, Mark ^l   Rasmussen, Steven A ^m   Hedges, Dawson ⁿ   Schweizer, Edward ^o   Uhlenhuth, Eberhard H ^p  

^a UNIVERSITY OF IOWA   (United States)

^b Dept Clin Sci Hoffmann La Roche ^*  (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d The New York Presbyterian Hospital   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF TEXAS AT DALLAS   (United States)

^g TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

ⁱ MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^j UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^k MASSACHUSETTS GENERAL HOSPITAL   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m BROWN UNIVERSITY   (United States)

ⁿ UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^o UNIVERSITY OF PENNSYLVANIA   (United States)

^p UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^q EAST TENNESSEE STATE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAL HYDRATE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOCIAL PHOBIA; XEROSTOMIA;

ADULT; BENZAMIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITORS; PHOBIC DISORDERS; PSYCHIATRIC STATUS RATING SCALES;

EID: 0343683384     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199708000-00002     Document Type: Article

References (48)

1. Marks IM. The classification of phobic disorders. Br J Psychiatry 1970;116:377-86.
2. Davidson JR, Hughes DL, George LK, Blazer DG. The epidemiology of social phobia: findings from the Duke Epidemiological Catchment Area Study. Psychol Med 1993;23:709-18.
3. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen H-U, Kendler KS. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994;51:8-19.
4. Schneier FR, Johnson J, Hornig CD, Liebowitz MR, Weissman MM. Social phobia: comorbidity and morbidity in an epidemiologic sample. Arch Gen Psychiatry 1992;49:282-8.
5. Schneier FR, Heckelman LR, Garfinkel R, Campeas R, Fallon BA, Gitow A, Street L, Bene DD, Liebowitz MR. Functional impairment in social phobia. J Clin Psychiatry 1994;55:322-31.
6. Davidson JRT, Hughes DC, George LK, Blazer DG. The boundary of social phobia: exploring the threshold. Arch Gen Psychiatry 1994;51:975-83.
7. Schneier FR. Monoamine oxidase inhibitors, selective serotonin reuptake inhibitors, and other antidepressants in pharmacotherapy. In: Stein MB, ed. Social phobia: clinical and research perspectives. Washington, DC: American Psychiatric Press, 1995: 347-74.
8. Sutherland SM, Davidson JRT. Beta-blockers and benzodiazepine in pharmacotherapy. In: Stein MB, ed. Social phobia: clinical and research perspectives. Washington, DC: American Psychiatric Press, 1995:323-46.
9. Heimberg RG, Juster HR. Cognitive-behavioral treatments: literature review. In: Heimberg RG, Liebowitz MR, Hope DA, Schneier FR, eds. Social phobia: diagnosis, assessment and treatment. New York: Guilford Press, 1995:161-309.
10. Liebowitz MR, Gorman JM, Fyer AJ, Klein DF. Social phobia: review of a neglected anxiety disorder. Arch Gen Psychiatry 1985; 42:729-36.
11. Gorman JM, Liebowitz MR, Fyer AJ, Campeas R, Klein DF. Treatment of social phobia with atenolol. J Clin Psychopharmacol 1985;5:298-301.
12. Benca R, Matuzas W, Al-Sadir J. Social phobia, MVP and response to imipramine. J Clin Psychopharmacol 1986;6:50-1.
13. Liebowitz MR, Fyer AJ, Gorman JM, Campeas R, Levin A. Phenelzine in social phobia. J Clin Psychopharmacol 1986;6:93-8.
14. Versiani M, Mundim MD, Nardi AE, Liebowitz MR. Tranylcypromine in social phobia. J Clin Psychopharmacol 1988;8:279-83.
15. Reich J, Yates W. A pilot study of treatment of social phobia with alprazolam. Am J Psychiatry 1988;145:590-4.
16. Lydiard RB, Laria MT, Howell EF, Ballenger JC, Alprazolam in the treatment of social phobia. J Clin Psychiatry 1988;49:17-9.
17. Munjack DJ, Baltazar PL, Bohn PB, Cabe DD, Appelson AA. Clonazepam in the treatment of social phobia: a pilot study. J Clin Psychiatry 1990;51[suppl 5]:35-40.
18. Ontiveros A, Fontaine R. Social phobia and clonazepam. Can J Psychiatry 1990;35:439-41.
19. Reiter SR, Pollack MH, Rosenbaum JF, Cohen LS. Clonazepam in the treatment of social phobia. J Clin Psychiatry 1990;51:470-2.
20. Munjack DJ, Bruns J, Baltazar PL, Brown R, Leonard M, Nagy R, Koek R, Crocker B, Schafer S. A pilot study of buspirone in the treatment of social phobia. J Anxiety Disord 1991;5:87-98.
21. Schneier FR, Saoud JB, Campeas R, Fallon BA, Hollander E, Coplan J, Liebowitz MR. Buspirone in social phobia. J Clin Psychopharmacol 1993;13:251-6.
22. Van Ameringen MJ, Mancini C, Streiner DL. Fluoxetine efficacy in social phobia. J Clin Psychiatry 1993;54:27-34.
23. Bisserbe J-C, Lepine J-P, GRP Group. Moclobemide in social phobia: a pilot open study. Clin Neuropharmacol 1994;17[suppl 1]: S88-S94.
24. Liebowitz MR, Gorman JM, Fyer AJ, Campeas R, Levin AR, Sandberg D, Hollander E, Papp L, Goetz D. Pharmacotherapy of social phobia: an interim report of a placebo controlled comparison of phenelzine and atenolol. J Clin Psychiatry 1988;49:252-7.
25. Gelernter CS, Uhde TW, Cimbolic P, Arnkoff DB, Vittone BJ, Tancer ME, Bartko JJ. Cognitive-behavioral and pharmacological treatments of social phobia. Arch Gen Psychiatry 1991;48:938-45.
26. Liebowitz MR, Schneier FR, Campeas R, Hollander E, Hatterer J, Fyer A, Gorman J, Papp L, Davies S, Gully R, Klein DF. Phenelzine vs. atenolol in social phobia: a placebo controlled comparison. Arch Gen Psychiatry 1992;49:290-300.
27. Versiani M, Nardi AE, Mundim FD, Alves AB, Liebowitz MR, Amrein R. Pharmacotherapy of social phobia: a controlled study with moclobemide and phenelzine. Br J Psychiatry 1992;161:353-60.
28. van Vliet IM, den Boer JA, Westernberg HGM. Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor. Neuropsychopharmacology 1992;2:21-9.
29. Fahlen T, Humble M, Koczkas C, Nilsson HL. Social phobia and its treatment with brofaromine: efficacy regarding social phobia symptoms and personality traits [abstract]. Clin Neuropharmacol 1992;15[suppl 1]:64B.
30. Liebowitz MR, Schneier F, Gitow A, Feerick J. Reversible monoamine oxidase-A inhibitors in social phobia. Clin Neuropharmacol 1993;16[suppl 2):S83-S88.
31. Davidson JRT, Potts N, Richichi E, Krishnan R, Ford SM, Smith R, Wilson WH. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 1993;13:423-8.
32. Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW, Mantle JM, Serlin RC. Sertraline for social phobia: A double-blind, placebo-controlled crossover study. Am J Psychiatry 1995;152:1368-71.
33. van Vliet IM, den Boer JA, Westenberg HGM. Psychopharmacological treatment of social phobia: a double-blind placebo-controlled study with fluvoxamine. Psychopharmacology 1994;115:128-34.
34. Gieschke R, Schmid-Burgle W, Amrein R. Interaction of moclobemide, a new reversible monoamine oxidase inhibitor with oral tyramine. J Neural Transm 1987;26:97-104.
35. Burkard WP, Bonetti EP, Da Prada M, Martin JR, Pole P, Schaffner R, Scherschlicht R, Hefti F, Muller RKM, Wyss P-C, Haefely W. Pharmacological profile of moclobemide: a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther 1989;248:391-9.
36. Freeman H. Moclobemide. Lancet 1993;342:1528-32.
37. Norman TR, Burrows GD. A risk-benefit assessment of moclobemide in the treatment of depressive disorders. Drug Saf 1995;12:46-54.
38. Spitzer RL, Williams JBW, Gibbon M, First MB. Structured Clinical Interview for DSM-III-R - Patient Edition. Washington, DC: American Psychiatric Press, 1990.
39. Stein MB, Hazen AL, Eldridge GD, Walker JR. Structured Clinical Interview for DSM-III-R revised for use in the Hoffmann-La Roche Moclobemide Anxiety Disorders Program. Nutley, NJ: Hoffmann-La Roche, 1992.
40. Guy W. ECDEU assessment manual for psychopharmacology, rev ed. Rockville, MD: US Department of Health, Education, and Welfare, National Institute of Mental Health. Publication No. ADM 76-338, 1976.
41. Schleyer B, Aaronson C, Mannuzza S, Martin LY, Fyer AJ. Schedule for Affective Disorders and Schizophrenia, Lifetime Anxiety, Revised (SADS-LA-R). New York: New York State Psychiatric Institute, 1990.
42. Spitzer RL, Williams JBW, Gibbon M, First MB. Structured Clinical Interview for DSM-III-R Personality Disorders (SCID-II). Washington, DC, American Psychiatric Press, 1990.
43. Davidson JRT, Potts NLS, Richichi EA, Ford SM, Krishnan KRR, Smith RD, Wilson W. The Brief Social Phobia Scale. J Clin Psychiatry 1991;52[suppl 11]:48-51.
44. Davidson JRT, Miner CM, de Veaugh-Geiss J, et al. The Brief Social Phobia Scale: a psychometric evaluation. Psychol Med 1997;27:161-6.
45. Liebowitz MR. Social phobia. In: Klein DF, ed. Anxiety (Modern problems of pharmacopsychiatry series, vol. 22). New York: Karger, 1987:141-73.
46. Horner KJ, Juster HR, Brown EJ, Heimberg RG. Psychometric properties of the Liebowitz Social Anxiety Scale. Paper presented at the Annual Meeting of the Anxiety Disorders Association of America, Orlando, FL, March 1996.
47. Sheehan DV. The anxiety disease and how to overcome it. New York: Scribner and Sons, 1983.
48. International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia - a double-blind, placebo-controlled, clinical study. Eur Arch Psychiatry Clin Neurosci 1997;247:71-80.